GlaxoSmithKline's Arzerra flunks lymphoma trial, dashing plans for expanded use
20.05.2014 / Fierce Pharma
GlaxoSmithKline has missed out on a big new market for its blood cancer drug Arzerra. Approved to treat chronic lymphocytic leukemia, Arzerra (ofatumumab) failed to pass the test in a B-cell lymphoma trial. And now, Glaxo officials say they're giving up on the indication.